Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
ForDyne B.V. submitted a Form 144 notice reporting proposed sales of Common Stock on multiple dates in April 2026. The filing lists specific lots sold: 04/15/2026 (92,956 shares, $1,893,634.56), 04/16/2026 (6,657 shares, $133,522.78), 04/17/2026 (211,974 shares, $4,301,291.62), 04/20/2026 (125,274 shares, $2,513,898.41), 04/21/2026 (8,300 shares, $166,120.35), and 04/22/2026 (2,652 shares, $53,049.28). The Form references an IPO Conversion of Shares dated 09/17/2020 and lists UBS Financial Services as a broker on Nasdaq.
Dyne Therapeutics, Inc. amended its loan and security agreement with Hercules Capital, expanding its debt facility to an aggregate of up to $400.0 million and easing certain cash covenants.
Under the Second Amendment, Dyne immediately borrowed an additional $50.0 million tranche, bringing total outstanding principal under the loan agreement to $200.0 million. Three further term loan tranches totaling up to $125.0 million are available upon achieving specified clinical, regulatory and commercial milestones, plus a final tranche of up to $75.0 million subject to lender investment committee approval.
The amendment shifts the initial minimum cash covenant testing date to July 1, 2027 (with a potential extension to July 1, 2028 if financing milestones are met) and reduces the initial required cash level from 60% to 40% of then-outstanding obligations, tested only if Dyne’s market capitalization is less than $1.65 billion. The debt matures on July 1, 2030, bears interest at the Wall Street Journal prime rate (floor 7.50%) plus 2.45%, and is interest-only until July 1, 2029, with potential extension to maturity upon meeting milestones. The facility is secured by a first-priority security interest in substantially all company assets, including intellectual property.
DYN affiliate filings report proposed and recent transactions in Common Stock. The excerpt shows 3,311 shares sold on 05/13/2026 by John Cox and a planned disposition of 9,081 Restricted Stock Units dated 06/04/2026 described as Equity Compensation. The broker listed is Stifel Nicolaus & Company Inc. Shares outstanding are shown as 165,313,769 as of 06/16/2026.
Dyne Therapeutics, Inc. director Edward Hurwitz received a grant of stock options as part of his compensation. The award covers 35,152 stock options, each exercisable for one share of common stock at an exercise price of $17.04 per share. According to the disclosure, these options were granted on June 5, 2026 and will vest in full on the earlier of June 5, 2027 or the company’s 2027 Annual Meeting of Stockholders, provided he continues in service. Following this grant, Hurwitz holds 35,152 derivative securities from this award.
Dyne Therapeutics director David Charles Lubner received a new stock option grant covering 35,152 shares of common stock. The option has an exercise price of $17.04 per share and expires on June 4, 2036. All 35,152 underlying shares are scheduled to vest in full on the earlier of June 5, 2027 or the company’s 2027 Annual Meeting of Stockholders, subject to his continued service. After this grant, Lubner holds 35,152 stock options directly. This is a compensation-related award rather than an open-market purchase or sale.
Dyne Therapeutics director Jason P. Rhodes received a grant of stock options for 35,152 shares of common stock. The options have an exercise price of $17.04 per share and expire on June 4, 2036. The shares underlying the option are scheduled to vest in full on the earlier of June 5, 2027 or the company’s 2027 annual stockholder meeting, subject to continued service. Rhodes is obligated to transfer any economic benefit from shares issued on exercise to Atlas Venture Life Science Advisors, and he disclaims beneficial ownership except for any pecuniary interest.
Dyne Therapeutics director Dirk Kersten received a new stock option grant as part of his compensation. On June 5, 2026, he was awarded options covering 35,152 shares of common stock at an exercise price of $17.04 per share.
The option vests in full on the earlier of June 5, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as Kersten continues to serve the company. After this grant, he holds 35,152 stock options directly, and there are no additional derivative holdings shown in this filing.
Dyne Therapeutics, Inc. director Carlo Incerti received a grant of stock options on June 5, 2026. The award covers 35,152 options to purchase Common Stock at an exercise price of $17.04 per share, held directly.
The options expire on June 4, 2036 and are scheduled to vest in full on the earlier of June 5, 2027 or the date of Dyne Therapeutics’ 2027 Annual Meeting of Stockholders, provided Incerti continues in service. Following this grant, he holds 35,152 derivative securities linked to common shares.
Dyne Therapeutics director Catherine Stehman-Breen received a new stock option grant as part of her compensation. On June 5, 2026 she was awarded options to purchase 35,152 shares of Dyne Therapeutics common stock at an exercise price of $17.04 per share.
The option vests in full on the earlier of June 5, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as she continues to serve. Following this grant, she holds 35,152 stock options directly under this award, which expire on June 4, 2036.
Dyne Therapeutics director Brian S. Posner reported two insider transactions. He made an open-market purchase of 2,000 shares of common stock at $16.94 per share, bringing his directly held stake to 24,500 shares.
He also received a grant of stock options covering 35,152 shares of common stock with an exercise price of $17.04 per share. According to the disclosure, these options vest in full on the earlier of June 5, 2027 or the date of Dyne Therapeutics’ 2027 annual stockholders’ meeting, subject to his continued service.